Pivotal acquisition in Envision Pharma Group's tech-enabled offerings provides clients with access to advanced AI to accelerate decision-making that optimizes their products' path to market and ultimately supports the delivery of enhanced patient outcomes.

Hyris is going to present its new test to detect the body's T Cell immune response to SARS-CoV-2 on 17 December 2021, at "A-WISH", Alicante-Winter Immunology Symposium in Health, which will address strategies for the COVID-19 response and the development of the vaccines against SARS-CoV-2. This new solution leverages the Hyris System™, a proprietary platform that enables genetic testing in any setting, at any time, with results available in real-time through its AI-powered platform.

Xevant continues to take steps forward within the pharmacy benefits industry, successfully completing its SOC 2 Type 1 audit.